BIIB · Biogen Inc.
$209.83
-0.82 (-0.39%)
At close · Aug 14
Market Cap
$30.98B
Shares
147.64M
Biogen Inc. Earnings Call Transcripts
Every quarterly earnings call for Biogen Inc. (BIIB) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼9.7%
$2.51B
$1.13B
'22 Q3
22-10-25
▼6.9%
$2.54B
$550.40M
'22 Q4
23-02-15
▼2.7%
$2.46B
$387.90M
'23 Q1
23-04-25
▼5.1%
$2.46B
$591.60M
'23 Q2
23-07-25
▲0.9%
$2.53B
−$68.10M
'23 Q3
23-11-08
▼6.2%
$2.39B
$249.70M
'23 Q4
24-02-13
▼7%
$2.29B
$393.40M
'24 Q1
24-04-24
▲0.4%
$2.46B
$583.60M
'24 Q2
24-08-01
▼2.5%
$2.47B
$388.50M
'24 Q3
24-10-30
▲2.9%
$2.45B
$266.70M
'24 Q4
25-02-12
▲6.1%
$2.43B
$240.50M
'25 Q1
25-05-01
▲7.3%
$2.65B
$634.80M
'25 Q2
25-07-31
▲2.8%
$2.53B
$466.50M
'25 Q3
25-10-30
▼7.1%
$2.28B
−$48.90M
'25 Q4
26-02-06
LATEST
▲1.9%
$2.48B
$319.50M
'26 Q1
26-04-29
Earnings call
FY26 · Q2
2026-07-01
Biogen Inc. Q2 FY2026 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-04-29
Biogen Inc. Q1 FY2026 Earnings Call
Confident tone
Leqembi franchise and care pathway
Pellas/Pelagos acquisition
Growth product momentum
Revenue
$2.48B
▲ 1.9% YoY Diluted EPS
$2.15
▲ 31.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-06
Biogen Inc. Q4 FY2025 Earnings Call
Confident tone
Leqembi (Lakembi) franchise and iClick
Spinraza high-dose and SMA
European pricing, MFN, and ex-US rollout
Revenue
$2.28B*
▼ 7.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Biogen Inc. Q3 FY2025 Earnings Call
Confident tone
Launch product momentum
Late-stage pipeline and readouts
Tau / BIIB080 readout and external data read-throughs
Revenue
$2.53B
▲ 2.8% YoY Diluted EPS
$3.17
▲ 19.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Biogen Inc. Q2 FY2025 Earnings Call
Confident tone
LEQEMBI / Alzheimer's franchise
Pipeline progress and milestones
Eisai partnership / Europe arbitration
Revenue
$2.65B
▲ 7.3% YoY Diluted EPS
$4.33
▲ 8.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Biogen Inc. Q1 FY2025 Earnings Call
Positive tone
Pipeline and external innovation
LEQEMBI launch and growth
Alzheimer's prevention trials
Revenue
$2.43B
▲ 6.1% YoY Diluted EPS
$1.64
▼ 39.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-12
Biogen Inc. Q4 FY2024 Earnings Call
Positive tone
LEQEMBI growth and Alzheimer's franchise
New product launches offsetting MS decline
Pipeline reprioritization and future readouts
Revenue
$2.45B*
▲ 2.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-30
Biogen Inc. Q3 FY2024 Earnings Call
Positive tone
ZURZUVAE launch
SKYCLARYS global expansion
LEQEMBI launch
Revenue
$2.47B
▼ 2.5% YoY Diluted EPS
$2.66
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Biogen Inc. Q2 FY2024 Earnings Call
Confident tone
LEQEMBI and Alzheimer's franchise
Business development and M&A (HI-Bio)
New product launches (SKYCLARYS, ZURZUVAE, Reata)
Revenue
$2.46B
▲ 0.4% YoY Diluted EPS
$4.00
▼ 1.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-24
Biogen Inc. Q1 FY2024 Earnings Call
Positive tone
LEQEMBI launch and Alzheimer's market
Quarterly financial performance
SKYCLARYS launch and rare disease
Revenue
$2.29B
▼ 7% YoY Diluted EPS
$2.70
▲ 1.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-13
Biogen Inc. Q4 FY2023 Earnings Call
Confident tone
LEQEMBI (Alzheimer's disease franchise)
SKYCLARYS launch and Friedreich's Ataxia
International expansion (Japan, Europe, Latin America)
Revenue
$2.39B*
▼ 6.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Biogen Inc. Q3 FY2023 Earnings Call
Revenue
$2.53B
▲ 0.9% YoY Diluted EPS
$-0.47
▼ 106% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-25
Biogen Inc. Q2 FY2023 Earnings Call
Revenue
$2.46B
▼ 5.1% YoY Diluted EPS
$4.07
▼ 43.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-25
Biogen Inc. Q1 FY2023 Earnings Call
Revenue
$2.46B
▼ 2.7% YoY Diluted EPS
$2.67
▲ 29.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-15
Biogen Inc. Q4 FY2022 Earnings Call
Revenue
$2.54B*
▼ 6.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-25
Biogen Inc. Q3 FY2022 Earnings Call
Revenue
$2.51B
▼ 9.7% YoY Diluted EPS
$7.84
▲ 253.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-20
Biogen Inc. Q2 FY2022 Earnings Call
Revenue
$2.59B
▼ 6.7% YoY Diluted EPS
$7.24
▲ 142.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Biogen Inc. Q1 FY2022 Earnings Call
Revenue
$2.53B
▼ 6% YoY Diluted EPS
$2.06
▼ 23.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-03
Biogen Inc. Q4 FY2021 Earnings Call
Revenue
$2.73B*
▼ 4.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-20
Biogen Inc. Q3 FY2021 Earnings Call
Revenue
$2.78B
▼ 17.7% YoY Diluted EPS
$2.22
▼ 50.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-22
Biogen Inc. Q2 FY2021 Earnings Call
Revenue
$2.77B
▼ 24.6% YoY Diluted EPS
$2.99
▼ 68.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-22
Biogen Inc. Q1 FY2021 Earnings Call
Revenue
$2.69B
▼ 23.8% YoY Diluted EPS
$2.69
▼ 66.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-03
Biogen Inc. Q4 FY2020 Earnings Call
Revenue
$2.85B
▼ 22.3% YoY Diluted EPS
$2.32
▼ 71.3% YoY Gross margin
82.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-21
Biogen Inc. Q3 FY2020 Earnings Call
Revenue
$3.38B
▼ 6.2% YoY Diluted EPS
$4.46
▼ 46.8% YoY Gross margin
86.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-22
Biogen Inc. Q2 FY2020 Earnings Call
Revenue
$3.68B
▲ 1.8% YoY Diluted EPS
$9.59
▲ 22.2% YoY Gross margin
88.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-22
Biogen Inc. Q1 FY2020 Earnings Call
Revenue
$3.53B
▲ 1.3% YoY Diluted EPS
$8.08
▲ 13% YoY Gross margin
87.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-30
Biogen Inc. Q4 FY2019 Earnings Call
Revenue
$3.67B
▲ 4.1% YoY Diluted EPS
$8.08
▲ 70.8% YoY Gross margin
87.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 earnings calls
Key facts
CIK
875045
CUSIP
09062X103
13F (30d)
947 filings
910 filers
Visit website
Investor relations